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Abstract 
 Many individuals who have suffered from spinal cord injury (SCI) have 
longstanding damage. The molecular environment of the spinal cord is not permissive to 
axonal growth and neuroplasticity after injury is limited. Perineuronal nets containing 
chondroitin sulfate proteoglycans (CSPGs) are major inhibitors of axonal sprouting. Our 
laboratory has identified that the transcription factor SOX9 regulates a battery of genes 
involved in CSPG biosynthesis. Using Sox9 conditional knockout mice, we have shown 
that ablating Sox9 before injury decreases CSPG levels in the cord, increases reparative 
sprouting, and leads to improved locomotor recovery. However, it is unknown whether 
Sox9 ablation following SCI leads to similar recovery. To investigate this, Sox9 was 
ablated in mice 30 days after SCI. This ablation did not decrease levels of perineuronal 
nets, increase neuroplasticity or improve locomotor recovery compared to controls. These 
results will be discussed in the context of CSPG turnover rate and matrix 
metalloproteinase activity.  
Keywords 
Spinal cord injury, Sox9, chondroitin sulfate proteoglycans, perineuronal nets, 
neuroplasticity, axonal sprouting, matrix metalloproteinases. 
 
 
 
 
 
	 ii	
Co-authorship Statement 
This thesis has been prepared to be published in the future and is co-authored by 
myself, Russell MacMillan, Dr. Nicole Geremia, Dr. Todd Hryciw, Dr. Kathy Xu, and 
Dr. Arthur Brown. Russell MacMillan assisted with the quantification of BDA. Dr. 
Nicole Geremia was the second observer in hindlimb movement assessment using the 
Basso Mouse Scale. Dr. Todd Hryciw performed the BDA injections to label 
corticospinal tract fibres and provided guidance when I carried out qPCR and assessed 
mRNA expression levels. Dr. Kathy Xu assisted with genotyping the mice. I planned and 
performed the experiments, and carried out the statistical analysis of data with the 
assistance of those mentioned above. Dr. Andreas Schedl provided the Sox9f/f mice. Dr. 
Arthur Brown provided direction in the design of the study, provided guidance and 
support, and edited the written thesis.  
 
 
 
 
 
 
 
 
 
 
 
	 iii	
Acknowledgments 
I would like to thank Dr. Arthur Brown for giving me the opportunity to work in 
his laboratory and perform meaningful research with his team of scientists. Dr. Brown has 
always been an incredibly supportive mentor, providing encouragement and guidance 
throughout my time as his graduate student. I would also like to extend my thanks to the 
members of the Brown laboratory: Dr. Nicole Geremia, Dr. Kathy Xu, Dr. Todd Hryciw, 
Tony Liu, and Corey Fletcher. Thank you for being such great lab-mates, providing 
laughs, advice, and assistance with my work. Thank you to the members of my advisory 
committee Dr. Susanne Schmid and Dr. Brian Allman for your suggestions and direction. 
Furthermore, I would like to thank my supportive group of friends for their 
encouragement through stressful times. Kate Merritt, Michelle Tran, Ramina Adam, 
Alenka Bullen, Katie Hill, Jackie Prazmowski and Alex Major thanks for always being 
there, and for the fun and memorable times outside of the lab. Lastly, I would like to say a 
special thanks to my parents Irena and Mariusz Ossowski for all of their love and support. 
 
 
 
 
 
 
 
 
 
	 iv	
Table of Contents 
Abstract ............................................................................................................................... i 
Keywords ............................................................................................................................ i 
Co-authorship .................................................................................................................... ii 
Acknowledgements .......................................................................................................... iii 
Table of Contents .............................................................................................................. iv 
List of Tables .................................................................................................................... vi 
List of Figures .................................................................................................................. vii  
List of Abbreviations ...................................................................................................... viii 
Chapter 1: Introduction ...................................................................................................... 1 
1.1 Spinal Cord Injury ……......................................................................................... 1 
1.2 Biochemical Events Following SCI ....................................................................... 2 
1.3 Neuroplasticity ...................................................................................................... 4 
1.4 Perineuronal Nets .................................................................................................. 5 
1.5 Chondroitin Sulfate Proteoglycans ........................................................................ 6 
1.6 Targeting CSPGs as a treatment for SCI ............................................................... 8 
1.7 Identification of the transcription factor SOX9 as regulator of CSPG levels ....... 9 
1.8 SOX9 ................................................................................................................... 10 
1.9 SOX9 and CSPG related gene expression ........................................................... 12 
1.10 Ablation of Sox9 prior to SCI increases reparative sprouting and improves 
locomotor recovery ................................................................................................... 13 
1.11 Rationale for current study ……….................................................................... 15 
1.12 Hypothesis and prediction ................................................................................. 16 
Chapter 2: Methods .......................................................................................................... 17 
2.1 Sox9 Conditional KO Mice ................................................................................. 17 
2.2 Spinal Cord Injury ............................................................................................... 19 
2.3 Sox9, Neurocan, Aggrecan, GFAP and Col4a1 Expression Following Tamoxifen 
Administration ........................................................................................................... 20 
2.4 Quantitative PCR ................................................................................................. 22 
2.5 Corticospinal Tract Anterograde Labeling .......................................................... 23 
2.6 Spinal Cord Sectioning......................................................................................... 23 
	 v	
2.7 Histological Staining............................................................................................ 24 
2.8 Quantification of WFA and BDA ........................................................................ 25 
2.9 Behavioral Testing ………………………........................................................... 25 
2.10 Statistical Analyses ………………………........................................................ 26 
Chapter 3: Results …........................................................................................................ 27 
3.1 Sox9 mRNA expression levels after onset of tamoxifen administration ............. 27 
3.2 Neurocan, Aggrecan, Gfap and Col4a1 mRNA expression levels after onset of 
tamoxifen administration ........................................................................................... 27 
3.3 Sox9 conditional knockout mice do not have reduced levels of perineuronal net 
matrix ....................................................................................................................... 32 
3.4 Sox9 conditional knockout mice do not have increased levels of corticospinal tract 
fibres .......................................................................................................................... 34  
3.5 Sox9 conditional knockout mice do not have improved locomotor recovery ..... 37  
Chapter 4: Discussion ....................................................................................................... 40 
References ........................................................................................................................ 51 
Ethics Approval for the Use of Animals on Protocol 2015-004 ...................................... 59 
CurriculumVitae ............................................................................................................... 60 
 
 
 
 
 
 
 
 
 
	 vi	
List of Tables 
Table 1: Taqman® Real Time PCR Primer Probe Sets. .................................................... 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vii	
List of Figures 
Figure 1: Representative gel of PCR products for the genotyping of Cre recombinase... 18 
Figure 2: Experimental timelines. .................................................................................... 21 
Figure 3: Sox9 mRNA levels at various time-points following the onset of tamoxifen 
administration. .................................................................................................................. 29 
Figure 4: Neurocan, aggrecan, GFAP and Col4a1 mRNA expression levels following the 
onset of tamoxifen administration. ................................................................................... 30 
Figure 5: WFA staining of perineuronal nets below the lesion in the ventral horns of 
control and Sox9 conditional knockout mice. .................................................................. 33 
Figure 6: BDA-labeled corticospinal tract fibres below the lesion in control and Sox9 
conditional knockout mice. .............................................................................................. 35 
Figure 7: Basso Mouse Scale for control and Sox9 conditional knockout mice following 
L1 SCI. ............................................................................................................................. 38 
Figure 8: Basso Mouse Scale for control and Sox9 conditional knockout mice following 
T9 SCI. ............................................................................................................................. 39 
Figure 9: Diagram describing how Sox9 ablation leads to increased neuroplasticity. ..... 45 
 
 
 
 
 
 
 
 
 
 
 
	 viii	
List of Abbreviations 
AMH – Anti-Müllerian hormone 
ANOVA – Analyses of Variance 
BDA – Biotinylated dextran amines 
BDNF – Brain-derived neurotrophic factor 
BMS – Basso Mouse Scale 
C4ST – Chondroitin 4-sulfotransferase 
cAMP – 3'-5'-cyclic adenosine monophosphate 
CD – Campomelic dysplasia 
ChABC – Chondroitinase ABC 
CNS – Central nervous system 
Col4a1 – Collagen alpha-1(IV)  
Cre – Cre recombinase  
CSPG – Chondroitin sulfate proteoglycan 
CST – Corticospinal tract 
EGFR – Epidermal growth factor receptor  
ER- Estrogen receptor 
ERK – Extracellular signal-regulated kinase 
GABA – Gamma aminobutyric acid 
GAG – Glycosaminoglycan 
GAP – Growth associated protein 
GFAP – Glial fibrillary acidic protein 
JNK – c-Jun N-terminal kinase 
KO – Knockout 
LAR – Leukocyte common antigen-related phosphatase 
LPS – Lipopolysacharide  
MMP – Matrix metalloproteinase 
NG2 – Neuron-glial antigen 2 
OD – Ocular dominance 
PBS – Phosphate-buffered saline 
PCR – Polymerase chain reaction 
	 ix	
PFA – Paraformaldehyde 
PNN – Perineuronal nets 
PNS – Peripheral nervous system 
PTPσ – Receptor protein tyrosine phosphatase σ 
SCI – Spinal cord injury 
SOX – Sry-type HMG box transcription factor 
VGLUT1 – Vesicular glutamate transporter 1 
WFA – Wisteria Floribunda agglutinin 
XT – Xylosyltransferase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
1	
Chapter 1: Introduction 
 
1.1 Spinal Cord Injury 
The spinal cord is responsible for the transfer of sensory and motor information 
between the brain and the rest of the body. Damage to the cord interrupts signaling to and 
from the brain, resulting in debilitating loss of sensation and motor control. In addition to 
these impairments, individuals with spinal cord injury (SCI) often suffer from chronic 
pain, spasms, difficulty breathing, sexual dysfunction and loss of bladder and bowel 
control (Masri and Keller, 2012; Elbasiouny et al., 2010; Zimmer et al., 2007; Hess and 
Hough, 2012; Benevento and Sipski, 2002). In Canada, it is estimated that 86,000 people 
live with SCI and about 4,300 new cases occur each year (Noonan et al., 2012; Farry, 
2010). Traffic accidents are the most common cause of SCI in North American, followed 
by falls (from both the ground level and from an elevation) (Singh et al., 2014). Due to 
the vast impact that SCI has on the health and quality of life of a person, the lifetime cost 
of an individual living with SCI in Canada can range from $1.5 to $3.0 million (Krueger 
et al., 2013) and the annual economic burden is $3.6 billion (Farry, 2010). Currently, 
there is no effective cure for SCI.  
The spinal cord is made up of a collection of neurons possessing long extensions 
called axons, which are responsible for the transport of signals. Injury to the neurons of 
the cord can result from physical trauma, which includes impact, persistent compression, 
stretching, and/or laceration (Dumont et al., 2001). This physical trauma is referred to as 
the primary injury (Dumont et al., 2001). A secondary injury follows the primary and 
intensifies damage. Ischemia, ischemia reperfusion, excitotoxicity, and immunologic 
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activation are all secondary injuries that occur following primary injury (Dumont et al., 
2001). The physical trauma and secondary damages that occur lead to the destruction of 
axons, resulting in loss of functional synaptic connections. Axons in the central nervous 
system do not naturally regenerate after SCI and thus, spontaneous recovery after injury is 
limited. 
 
1.2 Biochemical Events Following SCI  
Immediately following the mechanical trauma of SCI, microglia become activated 
and transform into macrophages (Popovich et al., 2002). These macrophages secrete 
inflammatory cytokines, proteases, and reactive oxygen species, which can lead to further 
cell injury in the cord (Fleming et al., 2006). However, these macrophages also engulf 
debris and secrete pro-regenerative cytokines and so have beneficial effects as well 
(Fleming et al., 2006). The blood-spinal cord barrier breaks down from the mechanical 
trauma of SCI and blood-borne inflammatory cells enter the cord (Hausmann, 2003). The 
first to arrive at the injury are neutrophils, seen just 4 hours post-SCI, peaking at 1-3 days 
and remaining high for 10 days in humans (Fleming et al., 2006.) Neutrophils release 
proteases and reactive oxygen species. Neutrophil elastase breaks down endothelial cells 
and is thought to increase heamorhage (Hausmann, 2003). In addition to neutrophils, 
blood-borne macrophages infiltrate the spinal cord through the disrupted blood-spinal 
cord barrier. Macrophages peak at 5-10 days after injury (Fleming et al., 2006). T-
lymphocytes also enter the spinal cord and are thought to kill specific cells and release 
cytokines (Hausmann, 2003). Lymphocytes seem to only appear in the human spinal cord 
weeks after injury (Fleming et al., 2006).  
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In addition to the inflammatory response after SCI, a variety of other biochemical 
events take place. Resident astrocytes become active, and proliferation and hypertrophy 
of these cells occur (Hausmann, 2003). Astrocytes secrete extracellular matrix proteins 
forming a glial scar, and release myelin associated neurite growth inhibitory factors 
(Hausmann, 2003). This response is thought to inhibit neuroplasticity after SCI. Another 
event that occurs as a result of SCI is increases of extracellular glutamate to toxic levels 
(Hausmann, 2003). Too much activation of NMDA glutamate receptors leads to an influx 
of Ca2+ into neurons which, through various secondary processes, results in cell death 
(Hausmann, 2003). Furthermore, the vascular damage that occurs from SCI results in 
hypoxia in the cord. A lack of oxygen leads to mitochondrial damage, energy depletion 
and subsequent cell death (Hausmann, 2003). 
At months to a year after SCI, microglia and macrophages are still present at the 
lesion but macrophages no longer express CD68, a marker of phagocytic macrophages 
(Fleming et al., 2006). It is unclear what the role of macrophages is in the chronically 
injured spinal cord (Fleming et al., 2006). In some cases, lymphocytes can be seen weeks 
to months after SCI (Fleming et al., 2006). In mice with SCI, it was found that B 
lymphocytes remain active in the spinal cord and systemically at 1 month post-injury, a 
chronic time-point in the mouse (Ankeny et al., 2006). Furthermore, at 42 days post-
injury there were higher levels of autoantibodies to CNS proteins and nuclear antigens in 
the sera of injured animals than in controls (Ankeny et al., 2006). A subset of these 
antibodies were found to be neurotoxic and could lead to inflammation (Ankeny et al., 
2006). In sera of patients with chronic SCI (greater than 12 months) high amounts of 
proinflammatory cytokines such as interleukein-2 and tumor necrosis factor alpha, were 
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found compared to controls (Hayes et al., 2002). These results demonstrate that 
inflammation after SCI persists well-past the acute phases, and are part of a multitude of 
studies that claim inflammation persists indefinitely (Schwab et al., 2014).   
 
1.3 Neuroplasticity 
Although recovery following SCI is quite limited, a moderate amount of spontaneous 
recovery does occur (Lynskey et al., 2008). For example, improvements in the ASIA 
Motor Score can be seen in quadriplegic and paraplegic patients within the first ten weeks 
following SCI (Curt et al., 2008). In animal models, stepping of rats (assessed using the 
Basso, Beattie and Bresnahan scale) improves over 42 days following a lateral thoracic 
hemisection (Ballermann and Fouad, 2006). This spontaneous recovery following SCI has 
been attributed mainly to the remyelination of spared axons and to neuroplasticity in the 
cord; that is, axonal sprouting of and the reorganization of spinal circuits (Bareyre et al., 
2004; Ballermann and Fouad, 2006; Courtine et al., 2008).  
Despite the limited ability of central nervous system (CNS) axons to regenerate, 
axons in the peripheral nervous system (PNS) are known to readily regenerate following 
injury (Abe and Cavalli, 2008). After injury, PNS neurons increase the expression of 
various factors necessary for regeneration such as the mitogen activated protein kinases c-
Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK), as well as 
certain transcription factors induced by cytokine release (Abe and Cavalli, 2008). 
Additionally, PNS neurons are thought to regenerate more readily because their molecular 
environment is more permissive to growth. Specifically, Schwann cells surround axons in 
the PNS, whereas axons in the CNS are surrounded by oligodendrocytes. It is thought that 
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Schwann cells provide an environment that is more permissive to regeneration, a 
hypothesis supported by the fact that when PNS and CNS neurons are transplanted into an 
environment high in Schwann cells, both are able to grow (David and Aguayo, 1981; 
Harvey and Plant, 1995). However, when transplanted into an environment rich in 
oligodendrocytes, PNS neurons show lack of growth (Fawcett et al., 1989). The increased 
production of growth promoting factors by Schwann cells following injury, and the 
presence of cell adhesion molecules on Schwann cell membranes are thought to 
contribute to their regeneration supporting properties (Fawcett and Keynes, 1990; Bixby 
et al., 1988).  
 
1.4 Perineuronal Nets  
In contrast to the PNS, the molecular environment of the CNS is not permissive to 
regeneration. A major barrier to neuroplasticity in the spinal cord is the presence of 
perineuronal nets (PNN) (Sorg et al., 2016). PNNs are extracellular matrix structures that 
surround the soma and proximal dendrites of certain neurons (Blosa et al., 2016). Their 
primary role is to stabilize synaptic connections and inhibit axonal sprouting (Blosa et al., 
2016). PNNs form near the end of development, after the establishment of synaptic 
circuitry and are known to correspond with the end of the critical period (time during 
development defined by high levels of plasticity in the CNS) (Wang and Fawcett, 2012). 
In studies where formation of mature synaptic connections during the early postnatal 
phase was inhibited by blocking normal neuronal activity, the formation of PNNs 
diminishes (Wang and Fawcett, 2012). For example, dark-rearing cats from birth, which 
decreases the sensory input of the visual system, prolonged the critical period in their 
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visual cortex and decreased the expression of Cat-301, Cat-315 and Cat-316 antigen, all 
components of PNNs (Lander et al., 1997; Wang and Fawcett, 2012).  
 
1.5 Chondroitin Sulfate Proteoglycans 
The main inhibitory component of PNNs is chondroitin sulfate proteoglycan (CSPG) 
(Wang and Fawcett, 2012). CSPGs are made up of a lectican protein core with covalently 
attached chains of chondroitin sulfate glycosaminoglycans (GAG) (Wang and Fawcett, 
2012). The number of GAG sidechains varies for different CSPGs. For example, the 
CSPG aggrecan contains around 100 GAG sidechains, while brevican and aggrecan 
contain between 0 to 5 (Siebert et al., 2014). The main group of CSPGs is the lectican 
group which includes aggrecan, neurocan, brevican and versican in its three isoforms 
(Siebert et al., 2014). These CSPGs are secreted by astrocytes and neurons. They contain 
a globular domain (G1) at their N-terminal and a G3 domain at their C-terminal (Siebert 
et al., 2014). Phosphacan is another type of CSPG and is a variant of the receptor protein 
tyrosine phosphatase (phosphacan does not have the tyrosine phosphatase intracellular 
domain (Siebert et al., 2014). The last CSPG is neuron-glial antigen 2 (NG2). NG2 is a 
transmembrane CSPG found on activated microglia, macrophages, oligodendrocyte 
progenitor cells and polydendrocytes (Sibert et al., 2014). In vivo and in vitro studies have 
demonstrated that axons do not extend into CSPG dense areas (Davies et al., 1997; 
McKeon et al., 1991). Furthermore, Pizzorusso et al. (2002) demonstrated the inhibitory 
effect of CSPGs on neuroplasticity in a study investigating plasticity in ocular dominance 
columns. During the postnatal phase, blocking sensory input from one eye (monocular 
deprivation) causes a shift in ocular dominance (OD) to the non-deprived eye (Pizzorusso 
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et al., 2002). However, in adulthood this ocular dominance shift does not occur. CSPGs in 
the brain are thought to inhibit axonal sprouting and consequently the ocular dominance 
shift (Pizzorusso et al., 2002). The authors injected chondroitinase ABC (ChABC), a 
bacterial enzyme that degrades CSPGs, into the visual cortex of rats and OD plasticity 
was evaluated. OD shifted towards the non-deprived eye in ChABC treated rats, 
demonstrating that CSPGs present in the visual cortex block activity dependent learning 
and neuroplasticity from occurring in the adult and that their degradation could create a 
new window of neuroplasticity (Pizzorusso et al., 2002).  
Within days following SCI, levels of CSPGs increase in the lesion area of the cord 
forming a major component of the glial scar (Lemons et al., 1999). A significant source of 
this increase in CSPGs is thought to be astrocytes (Lemons et al., 1999). Specifically, 
levels of the CSPGs neurocan, NG2, versican and brevican increase (Jones et al., 2003). 
Neurocan and versican levels remain elevated for 4 weeks after injury, while brevican 
levels are elevated for 2 months (Jones et al., 2003). NG2 peaks at 1 week following 
injury and remains increased for at least 7 weeks post-injury (Jones et al., 2002). The rise 
in CSPGs at the lesion is believed to protect intact tissue around the lesion from 
degradative enzymes present after SCI and from the inflammatory cells that lead to 
secondary damages (Fitch and Silver, 1997). However, the injury induced rise in CSPGs 
can create a microenvironment that inhibits neuroplasticity. 
As discussed above, CSPGs are inhibitory to axonal sprouting and are known to be an 
impediment to SCI recovery (Jones et al., 2003; Lemons et al., 1999; Wang and Fawcett, 
2012). CSPGs are thought to act as both a physical and molecular barrier to axonal 
growth. They bind to cell and substrate adhesion molecules, which are necessary for cell 
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migration, and block axons from binding these molecules (McKeon et al., 1995). CSPGs 
can also bind to growth factors such as heparin binding growth factor, and repulsive 
guidance molecules such as semaphorin 3A to modulate neuroplasticity (Deepa et al., 
2002; De Wit et al., 2005; Williams et al., 2010). In addition to acting as a binding 
scaffold, CSPGs have recently been shown to act as ligands to receptor protein tyrosine 
phosphatase σ (PTPσ) and leukocyte common antigen-related phosphatase (LAR) (Shen 
et al., 2009; Fry et al., 2010; Fisher et al., 2011). CSPG-mediated activation of PTPσ is 
thought to contribute to axonal growth inhibition since disruption of the PTPσ gene 
allows axons to infiltrate regions high in CSPGs (Shen et al., 2009). Blockade of LAR 
also eliminates CSPG mediated neurite growth inhibition and leads to locomotor recovery 
in mice after SCI (Fisher et al., 2011). Lastly, CSPGs are known to activate epidermal 
growth factor receptor (EGFR) leading to autophosphorylation of the receptor (Koprivica 
et al., 2005). When the kinase activity of EGFR was blocked, CSPG-mediated neurite 
outgrowth inhibition was neutralized, demonstrating that activation of EGFR may also be 
a mechanism through which CSPGs act to limit neuroplasticity (Koprivica et al., 2005).  
 
1.6 Targeting CSPGs as treatment of SCI 
 Anti-CSPG treatments for SCI show promise in increasing neuroplasticity and 
improving recovery following injury. Bradbury et al. (2002) were the first to demonstrate 
that treatment of rats with ChABC leads to functional improvement following SCI. The 
authors administered ChABC intrathecally in rats immediately after a C4 dorsal column 
crush (Bradbury et al., 2002). They found that there was increased regeneration of injured 
dorsal column axons and of corticospinal tract (CST) axons compared to control rats 
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(Bradbury et al., 2002). Furthermore, electrical stimulation of the motor cortex resulted in 
large postsynaptic cord dorsum potentials compared to controls, showing that CST 
functional connections increased (Bradbury et al., 2002). Lastly, ChABC treatement 
improved locomotor recovery as assessed by beam and grid walk (Bradbury et al., 2002).  
 Another method of reducing CSPGs is by targeting their synthesis. Grimpe and 
Silver (2004) decreased the expression of xylosyltransferase-1 (XT-1), an enzyme that 
initiates glycosylation of the protein backbone in CSPGs. By blocking glycosylation, the 
amount of GAG chains was reduced in the lesion and there was increased axonal 
regeneration of transplanted dorsal root ganglia axons around the lesion (Grimpe and 
Silver, 2004). In another study carried out by Takeuchi et al. (2015) the gene encoding the 
enzyme N-acetylgalactosaminyltransferase-1 was knocked out. This enzyme is 
responsible for the synthesis of the CSPG polysaccharide chain and thus knockout 
(KO) mice showed lower CSPG levels (Takeuchi et al., 2015). The KO animals also 
had higher serotonin immunoreactivity and increased corticospinal tract labeling, 
demonstrating that axon regrowth and/or sprouting occurred. Finally, the KO animals 
showed improved locomotor recovery as assessed with the Basso Mouse Scale (BMS) 
(Takeuchi et al., 2015).  
       
1.7 Identification of the transcription factor SOX9 as a regulator of CSPG levels 
 Despite the ability of ChABC to improve recovery after SCI in animals, the 
enzyme has characteristics that make it challenging to apply in humans. ChABC is not 
thermally stable, has a short half-life, and is not able to effectively cross the blood-brain-
barrier (Nazari-Robati et al., 2013; Zhao et al., 2011; Yang et al., 2015). Furthermore, a 
host of enzymes contribute to the synthesis of CSPGs thus, an upstream target would be a 
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more ideal candidate for treatment of SCI. XT-1 activity as well as activity of its isoform 
XT-2, are needed for the initiation of side chain synthesis (Grimpe and Silver, 2004; 
Ponighaus et al., 2007). These side chains are then sulfated, a process carried out by 
chondroitin 4-sulfotransferase (C4ST) (Yamauchi et al., 2000). In 2007, our lab sought to 
identify key regulators of XT-1, XT-2 and C4ST gene expression (Gris et al., 2007). 
Using in silico analysis, common transcription factor binding sites on the promoter 
regions of the three enzymes were identified in mouse, rat and human genes. SOX9 was 
identified as one of several transcription factors that could possibly regulate expression of 
XT-1, XT-2 and C4ST (Gris et al., 2007). Furthermore, when the expression profile of 
SOX9 was analyzed, it was found that 12 hours after SCI, SOX9 expression increased 12-
fold (Gris et al., 2007). This suggests that SOX9 could be an important player in CSPG 
formation post-SCI. 
 
1.8 SOX9 
 SOX9 is a member of the HMG-box class DNA binding proteins. This group of 
proteins recognizes a specific sequence in the minor groove of DNA (Lefebvre et al., 
1997). Three of the most well-known functions of the SOX9 transcription factor are male 
sex development, gliogenesis and chondrocyte differentiation. SOX9 interacts with 
steroidogenic factor 1 in Sertoli cells to increase expression of anti-Müllerian hormone 
(AMH) (Tanaka and Nishinakamura, 2014). AMH is needed for regression of the 
Müllerian duct, which is a critical step in developing the male phenotype. A mutation in 
SOX9 leads to autosomal sex reversal (Kwok et al., 1995).  
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In the CNS, glial cells express SOX transcription factors, and it was found that 
SOX9 specifically is involved in gliogenesis (Stolt et al., 2003). Mice with Sox9 ablated 
in neural stem cells have decreased levels of oligodendrocyte progenitors and astrocytes, 
but increased levels of motoneurons (Stolt et al., 2003). Furthermore, it was found that 
blocking SOX9 function in the subventricular zone using microRNA increases neuron 
cell number (Cheng et al., 2009).  
 In addition to autosomal sex reversal and disrupted gliogenesis, mutations in 
SOX9 often lead to the skeletal malformation syndrome Campomelic dysplasia (CD) 
(Kwok et al., 1995). Some of the cardinal features of CD include bowing and angulation 
of the femora and tibiae, hypoplastic scapulae, 11 pairs of ribs, dislocated hips, and pelvic 
abnormalities (Schafer et al., 1996). Non-skeletal abnormalities also occur including lack 
of olfactory bulb and tract formation, and cardiac and renal defects (Schafer et al., 1996). 
Most individuals afflicted with this congenital disease die within 1 week from cardiac 
failure (Schafer et al., 1996). A condition known as Pierre Robin Sequence can also arise 
when there are alterations in SOX9 activity due to mutations in chromosomal regions 
near the SOX9 gene (Selvi and Mukunda Priyanka, 2013). Pierre Robin Sequence results 
in abnormal development of facial features often leading to a small mandible, cleft palate, 
and glossoptosis (Selvi and Mukunda Priyanka, 2013).  
Dysregulation of SOX9 is thought to lead to the facial malformations in Pierre 
Robin Sequence and some of the skeletal abnormalities in Campomelic dysplasia due to 
its major role in regulating chondrogenesis (Selvi and Mukunda Priyanka, 2013; Ikeda et 
al., 2005). Bi et al. (1999) established Sox9-/- embryonic stem cells and examined the fates 
of Sox9-/- cells in mouse embryo chimeras. They found that in cartilage, Sox9-/- cells did 
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not undergo chondrogenic mesenchymal condensation; that is, they were arrested as 
mesenchymal cells and did not express chondrocyte markers Col2a1, Col9a2, Col11a2, 
and aggrecan (Bi et al., 1999). Furthermore, in teratomas that were derived from the Sox9-
/- embryonic stem cells, no cartilage formed (Bi et al., 1999). In another study, Sox9 
expression was ablated in limb buds before chondrogenic mesenchymal condensation 
(Akiyama et al., 2002). The ablation of Sox9 stopped chondrogenic mesenchymal 
condensation from occurring and resulted in the absence of cartilage and bone (Akiyama 
et al., 2002). This data demonstrates that SOX9 is necessary for the first step of 
chondrogenesis; the condensation of mesenchymal stem cells. The transcription factor 
also plays a role in regulating later stages of chondrogenesis. SOX9 binding sites are 
present in the enhancer regions of the chondrocyte related genes Col2a1, Col11a2 and 
CD-RAP (Lefebvre et al., 1997; Bridgewater et al., 1998; Xie et al., 1999). SOX9 is 
known to activate these enhancer regions and increase aggrecan expression in vitro, and 
to directly promote expression of Col2a1 in vivo in mice (Lefebvre et al., 1997; 
Bridgewater et al., 1998; Xie et al., 1999; Sekiya et al., 2000; Bell et al., 1997). In 
embryos where Sox9 expression was ablated after mesenchymal condensation, severe 
chondrodysplasia was present. The majority of cells remained as condensed mesenchymal 
cells (Akiyama et al., 2002). Because SOX9 plays a major role in the synthesis of 
extracellular matrix components, it was the ideal candidate to investigate as a key 
regulator in the formation of the SCI glial scar.  
 
1.9 SOX9 and CSPG related gene expression 
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 The first step in assessing whether SOX9 is a key player in the formation of the 
CSPG rich glial scar was to test whether it regulates the expression of CSPG-related 
genes. Gris et al. (2007) transfected rat primary astrocytes with a CMV-SOX9 expression 
construct to upregulate expression of the transcription factor. Increased Sox9 expression 
resulted in increased mRNA levels of XTI, XTII and C4ST (Gris et al., 2007). 
Furthermore, when Sox9 expression was knocked down using anti-SOX9 siRNA, levels 
of XTI, XTII and C4ST were significantly reduced (Gris et al., 2007). Similar expression 
patterns were discovered in vivo when Sox9 expression was ablated in the injured mouse 
spinal cord (McKillop et al., 2013). In this study, in addition to XTI and C4ST mRNA 
levels being reduced, other CSPG and glial scar-related genes including aggrecan, 
brevican, neurocan, Col2a1 and Col4a1 were reduced two weeks post-SCI (McKillop et 
al., 2013). Levels of CSPG protein and perineuronal net matrix were also reduced in Sox9 
KOs compared to controls (McKillop et al., 2013; McKillop et al., 2016). These results 
demonstrate that SOX9 regulates levels of CSPGs and could be targeted as a way of 
increasing neuroplasticity and improving recovery after SCI.  
   
1.10 Ablation of Sox9 prior to SCI increases reparative sprouting and improves 
locomotor recovery  
The next step in our laboratory’s investigation was to determine whether ablation 
of Sox9 could increase neuroplasticity and improve locomotor recovery after SCI. To 
assess this, Sox9 expression was ablated prior to a T9 SCI. Neuroplasticity in the Sox9 
KO and control mice was assessed by the levels of serotonin, synaptophysin, and 
vesicular glutamate transporter 1 (VGLUT1) immunoreactivity below the level of the 
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lesion, and by anterograde tract tracing studies. Hindlimb locomotor recovery in Sox9 
KOs and controls was assessed using the BMS. Ten weeks post-SCI, levels of serotonin 
immunoreactivity were found to be higher in Sox9 KO mice than in controls, immediately 
caudal to the lesion and in the lumbar enlargement (McKillop et al. 2016). In the 
anterograde tract tracing studies, biotinylated dextran amines (BDA) was injected into the 
motor cortex of control and Sox9 KO mice. Two weeks later, BDA levels around neurons 
below the level of the lesion were quantified. The amount of BDA positive puncta 
surrounding neurons in the ventral-half of the cord was increased in Sox9 KO mice 
compared to controls (McKillop et al., 2016). These results demonstrate that there is 
increased neuroplasticity in the cord following injury when Sox9 is ablated. To determine 
whether Sox9 KOs have increased neural input caudal to the lesion, synaptophysin and 
VGLUT1 were assessed. Increases were found in the number of synaptophysin+ and 
VGLUT1+ puncta, as well as the area of immunoreactivity for both markers in Sox9 KO 
mice compared to controls (McKillop et al., 2016). Furthermore, VGLUT1 was shown to 
co-localize with BDA demonstrating increased VGLUT+ release sites on the BDA 
labeled fibres (McKillop et al., 2016). Lastly, Sox9 KO mice had a higher BMS score at 
14 weeks post-SCI demonstrating that they recovered their hindlimb function more than 
controls (McKillop et al., 2013). Thus, conditional Sox9 ablation prior to SCI leads to 
reduced CSPG levels in the injured cord and improved locomotor recovery by increasing 
reparative sprouting. However, given that the majority of people with SCI have long-
standing disease, will conditional Sox9 ablation weeks after SCI also lead to reductions in 
CSPG levels, increased reparative sprouting and improved locomotor recovery? 
Investigating this question is the aim of the current study. 
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1.11 Rationale for current study 
 It is important to determine whether delayed ablation of Sox9 can increase 
neuroplasticity and improve recovery because many people have longstanding spinal cord 
injuries. These individuals would require treatment months to years after their injury, and 
my study will investigate whether targeting SOX9 in chronic SCI will be effective. In 
addition, targeting SOX9 weeks after SCI can help to define a window of treatment 
opportunity.  
There is contrasting support in the literature regarding whether ablating Sox9 
weeks after SCI will increase axonal sprouting and improve recovery. When Wang et al. 
(2011) administered ChABC to degrade PNNs in spinal cord injured rats 1 month after 
injury, they found increased numbers of axonal branches from corticospinal tract fibres 
crossing into both the grey and white matter rostral to the lesion. Furthermore, ChABC-
treated animals had increased colocalization of VGLUT1- and BDA-positive puncta in 
the dorsal CST, demonstrating that the CST fiber sprouting was associated with an 
increased presence of synaptic elements (Wang et al., 2011). However, rats did not show 
improvements in skilled paw reaching, ladder walk, or beam walk compared to 
penicillinase-treated controls. Another group, Lee et al. (2012), administered ChABC to 
mice three weeks post-SCI and observed improvements in hindlimb movement, assessed 
using the BMS. When the authors investigated levels of neuroplasticity by measuring 
densities of choline acetyletransferase-expressing cholinergic terminals and vesicular 
gamma aminobutyric acid (GABA) transporter-positive synaptic terminals around 
motorneurons in the ventral horn, they found no differences in ChABC-treated mice 
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versus controls (Lee et al., 2012). Furthermore, VGLUT1-positive synaptic terminals 
were quantified in lamina VII and IX and again, no differences were found between 
ChABC-treated and control mice (Lee et al., 2012). These results suggest that ChABC 
was not able to increase synaptic plasticity of cholinergic and inhibitory synapses in 
treated injured mice. Lastly, in a study carried out by Carter et al. (2011), spinal cord 
injured mice were treated with ChABC one month after injury. It was found that 
chondroitinase treatment had a neuroprotective effect on rubrospinal tract neurons in 
these animals. Delayed treatment was able to rescue soma atrophy and restore cell size 
eight weeks post-SCI (Carter et al., 2011).  
 Some of the results from these studies demonstrate the possibility of increased 
neuroplasticity and locomotor recovery when CSPGs are degraded weeks after SCI. 
These results also support my rationale that ablating Sox9 weeks after SCI can have 
similar effects. 
 
1.12 Hypothesis and Prediction 
I hypothesize that CSPG-rich PNNs limit neuroplasticity and recovery following 
SCI. I predict that ablating Sox9 several weeks after SCI will decrease PNN levels, 
increase neuroplasticity, and improve locomotor recovery in mice.  
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Chapter 2: Materials and Methods 
 
2.1 Sox9 Conditional KO Mice 
All protocols for these experiments were approved by the University of Western 
Ontario Animal Care Committee in accordance with the policies established in the Guide 
to Care and Use of Experimental Animals prepared by the Canadian Council on Animal 
Care. Sox9 conditional KO mice were used to investigate the effect of Sox9 ablation after 
SCI. A mouse strain (from Dr. Andreas Schedl) with floxed Sox9 alleles (loxP sites 
surrounding exon 2 and 3 of Sox9) (Akiyama et al., 2002) was bred with a transgenic 
mouse line expressing the enzyme Cre recombinase (Cre) fused to a mutated ligand 
binding domain of the mouse estrogen receptor (ER) under the control of a chimeric 
promoter/enhancer of the cytomegalovirus immediate-early enhancer and the chicken 
beta globin promoter/enhancer (Hayashi and McMahon, 2002). (Jackson Laboratories, 
Bar Harbor, Maine). Two groups of offspring were generated from this breeding; 
Sox9flox/flox;CAGGCreER mice (referred to as Sox9flox/flox;Cre) which were used as the 
conditional KO experimental group and Sox9flox/flox mice which were used as the control 
group. The Cre recombinase fused estrogen receptor (Cre-ER) does not bind estrogen, but 
readily binds the drug tamoxifen (Hayashi and McMahon, 2002). Tamoxifen 
administration was used to ablate Sox9 in the Sox9flox/flox;Cre mice, as when the drug binds 
Cre-ER in the cytoplasm, the complex is then free to enter the nucleus where it excises 
exons 2 and 3 of Sox9 (Hayashi and McMahon, 2002). Mice were genotyped using ear 
notch DNA amplified by polymerase chain reaction (PCR) (40 cycles) using the 
following primers:  
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Sox9flox allele:  5’-ACACAGCATAGGCTACCTG-3’ and 5’-
TGGTAATGAGTCATACACAGTAC-3’.  
Sox9wildtype allele:  5’-GGGGCTTGTCTCCTTCAGAG-3’ and 5’- 
TGGTAATGAGTCATACACAGTAC-3’. 
Sox9knock-out allele:  5’-GTCAAGCGACCCATG-3’ and 5’-
TGGTAATGAGTCATACACAGTAC-3’.  
Cre+ allele:   5’-CAATTTACTGACCGTACAC-3’ and  
5’-AGCTGGCCCAAATGTTGCTG-3’. 
 
 
 
 
 
 
 
 
 
 
 
 
+	 -	
Figure 1. Representative gel of PCR products for the genotyping of Cre 
recombinase. PCR products were run on 2% agarose gel and a 100 bp ladder 
was used. Top row of bands shows loading control interleukin-2 (324 bp) and 
bottom row of bands shows the presence or absence of Cre recombinase (100 
bp). Plus symbol signifies presence of Cre gene and minus symbol signifies 
its absence. 
Interleukin-2 
Cre recombinase 
+	 +	 +	 +	-	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
100 bp à 
324 bp à 
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Three weeks following SCI both experimental and control mice were treated with 
Tamoxifen (Sigma Aldrich, St. Louis, Missouri) dissolved in corn oil at 3mg/20g by oral 
gavage once a day for 7 days.  	
2.2 Spinal Cord Injury	
 Three weeks prior to tamoxifen treatment, 43 Sox9flox/flox;Cre and 42 Sox9flox/flox 
female mice weighing 20-25 grams were anesthetized using 3% isoflurane and 
maintained at 1.5% isoflurane and 30% oxygen. A dorsal laminectomy was performed to 
expose the L1 spinal cord segment. Forceps were used to stabilize the spinal cord at T12 
and L2. A 70 kdyne contusion SCI with a 1 second dwell time and 500-1000 µm 
displacement was performed at L1 using the computer controlled Infinite Horizons 
Impactor (Precision Systems and Instrumentation, Fairfax, Virginia). SCI surgeries were 
also performed at the T9 level on 18 Sox9flox/flox;Cre and 14 Sox9flox/flox mice. Mice were 
given buprenorphine (0.01 mg/kg, Schering-Plough, Hertfordshire, UK), Baytril (20 
mg/kg, Bayer, Toronto, Ontario, Canada) and 1 mL of 0.9% saline solution 
subcutaneously immediately after surgery. Buprenorphine and Baytril injections were 
continued for three days post SCI. Mice were housed individually for a week following 
surgery to ensure sutures were not pulled out by fellow mice during the healing process, 
and then were pair or triple housed. Bladders of mice were manually expressed twice 
daily throughout the experiment. 
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2.3 Sox9, Neurocan, Aggrecan, GFAP and Col4a1 Expression Following Tamoxifen 
Administration 
To determine how long after tamoxifen administration Sox9 mRNA levels are 
significantly reduced, a subset of Sox9flox/flox (control) and Sox9flox/flox;Cre (KO) mice with 
an L1 injury was perfused at 0, 3, 6, 9 and 14 days after the first tamoxifen administration  
(Figure 2). These animals were also used to study the expression levels of the CSPGs 
neurocan and aggrecan, as well as glial fibrillary acidic protein (GFAP) a marker of 
astrocyte activation, and collagen alpha-1(IV) (Col4a1) a glial scar gene. For RNA 
quantification, mice were cardiac perfused with 0.9% saline, and 5 mm segments of 
spinal cord were removed from the lesion and lumbar area below the lesion. Quantitative 
PCR was used to quantify RNA levels.  
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SCI recovery following delayed Sox9 ablation experiment timeline A 
Sox9, Neurocan, Aggrecan, GFAP and Col4a1 expression after 
tamoxifen administration 
experiment timeline 
 
B 
Day 29 Day 26 Day 34 
Spinal cord 
Injury (n=28 
control; n=27 
KO) 
Day 0 Day 21 Day 23 
Tamoxifen (n=21 
control; n=20 KO) 
Perfusions (n=4 
control and KO) 
Perfusions 
(n=4 control 
and KO) 
Perfusions 
(n=4 control 
and KO) 
Perfusions (n=5 
control and 
KO) 
Perfusions 
(n=8 control 
and n=7 KO) 
Spinal cord 
Injury 
(n=16 KO; n=14 
control and n=18 
KO; n=14 control) 
0 weeks  3 weeks 14 weeks 16 weeks 
Tamoxifen 
Treatment  
(n=9 KO; n=11 
control and n=10 
KO; n=13 control) 
Basso Mouse Scale 
(n=9 KO; n=9 control and n=10 KO; n=13 control) 
	
BDA 
Injection 
Perfusions for  
Histological Staining 
(BDA: n=7 KO; n=8 control, 
WFA: n=9 KO and control) 
Reductions in animal group number  
Tamoxifen treatment- 2 KO and 1 control due to too high BMS score at 24hr, 4 KO and 1 control showed self-
mutilation, 1 KO and 1 control had poor recovery/were ill 
BMS and Wisteria Floribunda Agglutinin (WFA)- 1 control was an outlier and 1 control died 
BDA- 2 KO and 1 control due to insufficient labeling efficiency 
Tamoxifen treatment- 1 control and 5 KO due to too high BMS score after 24hr, 1 KO showed self-mutilation, 
and 2 KO from spasm due to bladder expression 
 
* Orange represents animals in L1 lesion study and purple represents T9 lesion study 
Figure 2. Experimental timelines. A) Timeline of experiment assessing SCI 
recovery in Sox9 KO mice versus controls following Sox9 ablation weeks after 
injury. B) Timeline of experiment quantifying Sox9, neurocan, aggrecan, GFAP and 
Col4a1 mRNA levels at various time-points following the administration of 
tamoxifen. 
Reductions in animal group numbers: 
2 KO and 1 control due to self-mutilation 
1 KO and 1 control due to poor recovery/were ill 
1 control from spasm due to bladder expression 
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2.4 Quantitative PCR 
 Spinal cord tissue was placed in 1 mL of TRIzol (Life Technologies, Carlsbad, 
California) and lysed on ice using a syringe and 25-gauge needle. The tissue was stored in 
TRIzol at -80°C. Chloroform was mixed into the tissue containing solution and 
centrifuged at 4°C. The aqueous layer was removed and saved. Equal parts of 70% 
ethanol were mixed into the aqueous solution. RNA was purified using the RNeasy Mini 
Kit (QIAGEN, Valencia, California). Complementary DNA was synthesized using the 
high capacity cDNA reverse transcriptase kit (Applied Biosystems, Foster City, 
California) and the GeneAmp® PCR System 2400 device (Perkin Elmer, Waltham, 
Massachusetts). The following thermal cycler conditions were used; 10 min at 25°C, 2 
hours at 37°C, and held at 4°C. Taqman® gene expression assays were performed using 
the primer probe sets listed in Table 1 (Applied Biosystems, Foster City, California).  
 
Table 1. Taqman® Real Time PCR Primer Probe Sets  
Primer Probe Catalog Number PCR CT Range 
GAPDH Mm99999915_g1 17.405-21.239 
Sox9 Mm00448840_m1 23.143-28.237 
GFAP Mm01253033_m1 17.312-21.036 
Neurocan Mm00484007_m1 24.391-27.964 
Collagen 4A1 Mm01210125_m1 24.307-28.145 
Aggrecan Mm00545807_m1 25.031-30.728 
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A ViiA 7 Real-Time PCR System was used for the gene expression assays. The 
following thermal cycler conditions were used; 95°C for 20 seconds followed by 40 
cycles at 95°C for 1 second, and 60°C for 20 seconds. Data was collected at the end of 
every cycle.  
  
2.5 Corticospinal Tract Anterograde Labeling 
 BDA (10 000 MW, D1956, Invitrogen, Waltham, MA) injected into the hindlimb 
motor cortex was used to label corticospinal tract fibres to assess levels of neuroplasticity 
in the spinal cord. At 14 weeks post-SCI mice were anesthetized and stabilized using a 
stereotaxic frame. A burr hole, 1.5 mm in diameter, was drilled over the right primary 
motor cortex. A Hamilton syringe (33 gauge needle) containing 0.4 µL 10% BDA in 
phosphate-buffered saline (PBS) (10,000 d, Molecular Probes, Invitrogen) was placed 
into the burr hole and lowered into the brain parenchyma at a depth of 0.5 mm from the 
cortical surface in four different areas surrounding the location of +1.5 mm lateral, -1 mm 
posterior to bregma (+1 mm lateral, -0.5 mm posterior, +2 mm lateral, -0.5 mm posterior, 
+1 mm lateral, -1.5 mm posterior; +2 mm lateral, -1.5 mm posterior) (Pronichev and 
Lenkov, 1998). BDA (0.1 µL per injection) was then injected into the cortex and the 
needle maintained in position for 1 min not to disrupt BDA diffusion. Two weeks after 
BDA injections, mice were cardiac perfused. 
 
2.6 Spinal Cord Sectioning 
 At 16 weeks post-SCI animals were deeply anesthetized using ketamine (100 
mg/kg) and xylazine (5 mg/kg) and cardiac perfusion was performed. Approximately 50 
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mL of 0.9% saline was first used to clear the animal’s vascular bed. This was followed by 
100 mL of 4% paraformaldehyde (4% PFA in 0.1 M phosphate buffer at pH 7.4). Spinal 
cords were removed and post fixed in 4% PFA for 4 hours. Cords were then transferred to 
and stored in 10% sucrose solution in 0.1 M phosphate buffer at pH 7.4, overnight at 4°C 
followed by 24 hours in 20% sucrose solution for cryoprotection. Tissue-Tek Optimum 
Cutting Temperature Compound (Sakura Finetek U.S.A. Inc, Torrance, California) was 
used over dry ice to embed and freeze spinal cords. Embedded cords were stored at -80°C 
until sectioned. Spinal cords were sliced into 16 µm thick cross-sections using a cryostat 
and thaw mounted onto SuperfrostTM Plus glass microscope slides (Fisher Scientific 
Company, Ottawa, Canada). Slides with spinal cord sections were stored at -20 °C. 
 
2.7 Histological Staining 
 Slides were thawed at room temperature for 30 minutes before being washed 
twice for ten minutes in 1% PBS solution. Sections were then treated with 5% goat serum 
and 0.5% triton-x-100 in PBS, and incubated in a humidified chamber at room 
temperature for two hours. For perineuronal net staining, slides were treated with 
biotinylated Wisteria Floribunda agglutinin (WFA, 1:100, Sigma Aldrich, St. Louis, 
Missouri) and incubated overnight at 4°C in the humidified chamber. The next day, slides 
were washed again three times for 10 minutes in 1% PBS solution and treated with 
streptavidin conjugated Alexa-Fluor 488 (1:750, Invitrogen, Carlsbad, California) and 
incubated at room temperature for two hours. For BDA staining, sections were treated 
with streptavidin conjugated Alexa-Fluor 488 (1:1000, Invitrogen, Carlsbad, California) 
for 45 minutes at room temperature. Slides were then washed in 1% PBS three times for 
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15 min, rinsed briefly in distilled water, and mounted with coverglass using 
VECTASHIELD® mounting media with DAPI (Vector Laboratories, Burlingame, 
California).  
 
2.8 Quantification of WFA and BDA 
 Histological staining was quantified using ImageJ Pro Plus (Media Cybernetics 
Inc, Bethesda, Maryland). Ten 16 µL thick spinal cord sections spaced 160 µL apart at the 
lumbar enlargement below the L1 lesion were analyzed for each animal. For WFA 
quantification, the right and left ventral horns were assessed in each spinal section 
whereas for BDA, both ventral and dorsal horns were assessed. WFA was quantified by 
setting a threshold for pixel intensity for positive staining in each image of the right and 
left ventral horn and the area of positive staining was used for analyses. BDA was 
quantified by counting the number of BDA positive fibres with a minimum length of 5 
µm. The amount of BDA positive staining at T10 was used to assess BDA labeling 
efficiency. 
 
2.9 Behavioral Testing 
 The BMS open field locomotor score was used to assess locomotor recovery in 
the mice (Basso et al., 2006). Two viewers, blind to the genotypes of the animals, 
evaluated each mouse 24 hours following SCI and mice with BMS scores greater than 0.5 
were excluded from the study so that the level of paralyses between all animals was 
equivalent. Locomotor activity was scored using the BMS weekly for 14 weeks post 
injury (Figure 2).   
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2.10 Statistical Analyses  
Mean values are expressed as ± SE. WFA and BDA histological staining was 
subjected to statistical analysis using the Student’s T-test. Sox9 and SOX9 target gene 
mRNA levels were subjected to two-way analyses of variance (ANOVA) with Šídák 
multiple comparisons test. BMS scores were subjected to two-way repeated measures 
ANOVA. All statistical tests were run using GraphPad Prism 6 software (GraphPad 
Software Inc, La Jolla, California) and a value of p < 0.05 was considered significant. 	
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Chapter 3: Results 
 
3.1 Sox9 mRNA expression levels after onset of tamoxifen administration 
 To assess the effects of ablating Sox9 weeks after SCI, a tamoxifen inducible 
conditional Sox9 knockout model was used. Tamoxifen was administered to 
Sox9flox/flox;Cre and Sox9flox/flox control mice three weeks post-SCI, once a day, for one 
week. It was unknown at what time-point following the onset of tamoxifen treatment, 
levels of Sox9 mRNA would be significantly reduced. Quantitative PCR was run to assess 
levels of Sox9 in the injured spinal cord at 0, 3, 6, 9 and 14 days following the start of 
tamoxifen treatment at the lesion and in the lumbar cord caudal to the lesion (here after 
referred to as ‘lumbar’). Nine days after the onset of tamoxifen administration, Sox9 
mRNA levels were significantly reduced in the Sox9flox/flox;Cre mice compared to controls 
at the lesion and lumbar spinal cord (Fig. 3). Thus, Sox9 was ablated by 30 days post-SCI. 
By day 14 after the onset of tamoxifen, Sox9 expression was reduced by approximately 
74.4% at the lesion (Fig. 3A) and 85.3% in the lumbar (Fig. 3B) spinal cord.  
 
3.2 Neurocan, Aggrecan, Gfap and Col4a1 mRNA expression levels after onset of 
tamoxifen administration 
 Messenger RNA levels of genes known to be regulated by SOX9, which are 
implicated in glial scar formation and astrocyte activation, were also assessed (Gris et al., 
2007). Neurocan levels were reduced at 6 and 14 days post-tamoxifen administration at 
both the lesion and lumbar spinal cord (Fig. 4A), while there was no difference in 
aggrecan expression (Fig. 4B). GFAP was significantly reduced 14 days after tamoxifen 
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administration at the lesion and lumbar area (Fig. 4C). No differences were found in the 
levels of Col4a1 (Fig. 4D).  
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Figure 3. Sox9 mRNA levels at various time-points following the onset of 
tamoxifen administration. Sox9 levels are significantly reduced in Sox9f/f;Cre 
mice after 9 days following tamoxifen treatment at the lesion (A) and lumbar (B) 
spinal cord. By day 14, Sox9 expression is reduced by approximately 74.4% at the 
lesion (A) and 85.3% in the lumbar (B) spinal cord. (* indicates statistically 
significant difference between groups, p < 0.05, Two-way ANOVA, Šídák 
multiple comparisons test; n=5 control and n=5 KO for day 9, n=8 control and n=7 
KO for day 14).  
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Figure 4. Neurocan, aggrecan, GFAP and Col4a1 mRNA expression levels following 
the onset of tamoxifen administration. Neurocan expression is significantly reduced at 
Day 6 and 14 after tamoxifen treatment in Sox9f/f;Cre mice compared to controls (A) 
while there are no differences in aggrecan mRNA levels (B). GFAP expression is 
significantly reduced at Day 14 following tamoxifen treatment (C). No differences in 
Col4a1 expression were found between Sox9f/f;Cre mice and controls after tamoxifen 
treatment (D). (* indicates statistically significant difference between groups, p < 0.05, 
Two-way ANOVA, Šídák multiple comparisons test; n=4 control and KO Day 6, n= 8 
control and n=7 KO Day 14). 	
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3.3 Sox9 conditional knockout mice do not have reduced levels of perineuronal net 
matrix 
 Perineuronal nets containing CSPGs limit neuroplasticity and recovery after SCI 
(Sorg et al., 2016). Our laboratory has shown that SOX9 regulates a battery of genes 
necessary for CSPG production (Gris et al., 2007; McKillop et al., 2013). When Sox9 
expression is ablated at the time of SCI, levels of CSPGs and PNNs decrease (McKillop 
et al., 2013; McKillop et al., 2016). However, it is unknown whether ablating Sox9 weeks 
after SCI also reduces levels of PNNs. To address this question, mice that had Sox9 
expression ablated 30 days post-SCI were used to assess levels of PNNs in the lumbar 
cord caudal to an L1 lesion. Spinal cord cross-sections were stained with WFA, a lectin 
that visualizes PNNs, and the area of positive staining in the ventral horns caudal to the 
lesion was assessed. No differences in the levels of PNNs were found between Sox9f/f;Cre 
mice (Sox9 KO) and Sox9f/f control mice (Figure 5). 
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Control Knockout 
Figure 5. WFA staining of perineuronal nets below the lesion in the ventral horns 
of control and Sox9 conditional knockout mice. Arrows point to PNNs. There is no 
difference in the level of perineuronal nets between Sox9 conditional KO and control 
mice. A) Representative photomicrograph of WFA staining in the ventral horn of 
control and Sox9 KO mice. Scale bar= 100 µM. B) Photomicrograph of perineuronal 
net surrounding a neuron. Blue is DAPI staining, scale bar= 100 µM. C) 
Quantification of WFA demonstrating no difference in PNN levels between control 
and Sox9 KO mice. (p ≥ 0.05, Two-tailed student’s t test; n= 9). 	
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3.4 Sox9 conditional knockout mice do not have increased levels of corticospinal 
tract fibres 
 It is possible that Sox9 ablation 30 days after SCI opens a window of opportunity 
for neuroplasticity to occur in the injured spinal cord by decreasing levels of CSPGs. In 
order to assess whether ablating Sox9 30 days post-SCI results in increased 
neuroplasticity, levels of BDA labelled corticospinal tract fibres were quantified. BDA 
was injected into the mouse hind limb motor cortex 14 weeks post-SCI to label 
corticospinal tract fibres. Two weeks later, lumbar cross-sections caudal to the lesion 
were stained for BDA. No differences in the number of BDA-labeled corticospinal tract 
fibres were found between Sox9 KO and control mice (Figure 6). 
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Figure 6. BDA-labeled corticospinal tract fibres below the lesion in control 
and Sox9 conditional knockout mice. There is no difference in the number of 
BDA fibres between Sox9 conditional KO and control mice. A) Representative 
photomicrograph of BDA staining at T10 rostral to the lesion which was used to 
assess labelling efficiency. Arrow shows the corticospinal tract bundle. B) Negative 
staining of an animal that did not have BDA injection into the motor cortex. Lack 
of BDA puncta can be noted. C/D) Representative photomicrograph of BDA 
staining in the ventral horn (outlined) of control and Sox9 KO mice. Arrowheads 
show BDA puncta. Scale bar= 100 µM. E) Quantification of BDA demonstrating 
no difference between control and Sox9 KO mice. (p ≥ 0.05, Two tailed student’s t-
test; n= 8 control and n= 7 KO). 	
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3.5 Sox9 conditional knockout mice do not have improved locomotor recovery  
 My next question was whether ablating Sox9 weeks after injury would lead to 
improved locomotor recovery. Locomotor recovery was evaluated in Sox9 KO and 
control mice after an L1 SCI by assessing hindlimb function using the BMS. The first 
BMS score was given 24 hours following SCI and mice with a score greater than 0.5 were 
excluded from the study. Mice that were kept in the study had a score of 0 or 0.5, 
translating to completely paralyzed hindlimbs or only slight ankle movement (less than 
90°) in one hindlimb (Basso et al., 2006). The BMS was then carried out once a week for 
14 weeks. Both control and Sox9 KO mice showed a gradual significant improvement in 
locomotor recovery with respect to time (Figure 7). Both groups reached a plateau at 42 
days post-SCI (Figure 7). Control mice attained a score of 3.11 ± 0.33 at 14 weeks (98 
days) post-SCI, a score which represents an ability to plantar place paws with or without 
weight support OR dorsal step but not plantar step (Figure 7; Basso et al., 2006). Sox9 
KO mice attained a score of 2.61 ± 0.29 which represents an ability to extensively move 
the ankle of one hindlimb, and plantar place the other hindlimb with or without weight 
support OR dorsal step but not plantar step that hindlimb (Basso et al., 2006).  
 After sacrificing the animals and performing lesion location analysis it was noted 
that the lesion was more caudal than expected and there was concern that a lesion on the 
lumbar enlargement would directly injure neurons involved in hindlimb movement. This 
is because the lumbar enlargement is the site of many motor neuron cell bodies, which 
supply the lower limbs. Thus, any neuroplasticity occurring below the lesion may not be 
reflected using the BMS. Because of this, I decided to perform a T9 injury on a new 
subset of mice (n= 10 KO and n=13 control) and assess hindlimb recovery using the BMS 
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(Figure 8). These mice demonstrated the same pattern of locomotor improvement with 
respect to time, and plateaued at approximately 28 days post-SCI. The location of the 
lesion did not change previous results; Sox9 KO showed no significant difference in 
hindlimb movement compared to control mice (Figure 8).   
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Figure 7. Basso Mouse Scale for control and Sox9 conditional knockout mice 
following L1 SCI. Both control and Sox9 conditional knockout mice display 
hindlimb paralysis immediately following SCI. Both groups show significant 
locomotor recovery with respect to time (p < 0.0001, Two-way repeated measures 
ANOVA, n=9). There were no significant differences in hindlimb function at 98 
days post-SCI between control and Sox9 conditional knockout mice. (p ≥ 0.05, 
Two-way repeated measures ANOVA; n=9).  
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Figure 8. Basso Mouse Scale for control and Sox9 conditional knockout mice 
following T9 SCI. Both control and Sox9 conditional knockout mice display 
hindlimb paralysis immediately following SCI. Both groups show significant 
locomotor recovery with respect to time (p < 0.0001, Two-way repeated measures 
ANOVA, n=13 control; n=10 KO). There are no significant differences in 
hindlimb function at 98 days post-SCI between control and Sox9 conditional 
knockout mice. (p ≥ 0.05, Two-way repeated measures ANOVA; n=13 control and 
n=10 KO).  
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Chapter 4: Discussion 
 
There are currently about 85,500 people living with SCI in Canada (Noonan et al., 
2012). The majority of individuals with SCI have longstanding disease and therefore it is 
important to investigate whether a treatment for SCI can be effective when administered 
at chronic time-points. In addition, knowing if a treatment is effective at later time-points 
can help define a treatment window for acute SCI. We have shown that ablating Sox9 just 
prior to SCI leads to decreased CSPG levels, increased reactive sprouting, and improved 
locomotor recovery in mice (McKillop et al., 2013; McKillop et al., 2016). CSPG-rich 
PNNs are a major impediment to neuroplasticity and are known to limit recovery after 
SCI (Sorg et al., 2016). SOX9 up-regulates a battery of genes necessary for CSPG 
production and thus, ablation of Sox9 can decrease CSPG levels and consequently reduce 
their inhibitory effect on axonal sprouting (Gris et al., 2007; McKillop et al., 2013).    
My study focused on modifying the molecular environment of the spinal cord to 
make it more permissive to axonal sprouting. I aimed to decrease PNNs in a chronic 
model of SCI by ablating the expression of Sox9 weeks after injury, and investigating 
whether Sox9 ablation can increase reactive sprouting and improve locomotor recovery. I 
used a tamoxifen inducible conditional Sox9 KO. The first question I addressed was how 
long following the onset of tamoxifen administration does it take for Sox9 expression to 
be significantly reduced. To answer this question, I measured levels of mRNA at the 
lesion (L1) and caudal to the lesion (rest of the lumbar spinal cord) at 0, 3, 6, 9, and 14 
days after the start of tamoxifen administration. I found that 9 days after the onset of 
tamoxifen treatment, Sox9 mRNA levels were significantly reduced in Sox9f/f;Cre mice 
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versus the Sox9f/f controls both at and below the lesion. Because tamoxifen treatment was 
initiated 3 weeks after SCI, this means that Sox9 mRNA was ablated 30 days post-injury.  
The next question addressed was whether ablating Sox9 30 days post-injury would 
effectively decrease CSPG levels and PNN matrix. Messenger RNA levels of two 
individual CSPGs, neurocan and aggrecan, were quantified. Neurocan was significantly 
decreased in Sox9 KO mice compared to controls at 6 and 14 days following the onset of 
tamoxifen administration, while no significant differences were seen in aggrecan levels. 
Previous work in my laboratory using both siRNA and tamoxifen inducible KO of Sox9 
in astrocyte cell culture has shown that SOX9 regulates expression of neurocan and 
aggrecan (Gris et al., 2007; McKillop et al., 2013). We have also shown that ablating 
Sox9 prior to SCI in mice decreases expression of these CSPGs at the lesion (McKillop et 
al., 2016). Therefore, I predicted that expression of both neurocan and aggrecan would be 
decreased following delayed Sox9 ablation. It is possible that I did not see changes in 
aggrecan levels because expression of this CSPG is known to drastically decrease 
following SCI and remains at very low levels at 28 days post-injury, thus detecting a 
change in expression when protein levels are already low can be difficult (Andrews et al., 
2012). This decrease in aggrecan is supported by my study which demonstrated that 
expression levels of aggrecan at 3 weeks post-SCI were approximately 30% that of 
neurocan expression.  
Two other genes known to be regulated by SOX9 are GFAP and Col4a1 (Gris et 
al., 2007). GFAP is the major intermediate filament in differentiated astrocytes (Eng, 
1985) and is a marker for astrogliosis (Eng and Ghirnikar, 1994). Col4a1 is a protein 
component of collagen 4, which is present in the lesion epicenter (Klapka and Muller, 
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2006). Expression of these genes was assessed in Sox9 KO and control mice after 
tamoxifen treatment. GFAP expression was reduced at 14 days following tamoxifen 
treatment. This decreased expression was expected as Sox9 levels were reduced by day 9. 
Hypertrophic astrocytes play a big role in glial scar formation after SCI by secreting 
CSPGs (Silver and Miller, 2004). Attenuating astrogliosis through Sox9 ablation can 
decrease CSPGs and their inhibitory effect on axon outgrowth. No difference in Col4a1 
expression was found between Sox9 KO and control mice. We have shown in a previous 
study that Sox9 ablation prior to SCI in mice reduces levels of Col4a1 (McKillop et al., 
2013). Thus, in chronic phases of SCI, expression of Col4a1 is no longer regulated by 
SOX9 activity as it is in the acute phase.    
At 16 weeks post-SCI, the lesion and lumbar area of the cord caudal to the lesion 
were stained with WFA to quantify PNN matrix. No significant differences were found 
between the Sox9 KO mice and controls. These results demonstrate that ablating Sox9 30 
days post-SCI is too late to decrease levels of PNN matrix in the spinal cord. The PNN 
matrix is composed of many different CSPGs including neurocan, aggrecan, brevican, 
and versican (Deepa et al., 2006). Decreased levels of just one type of CSPG is likely not 
enough to reduce WFA staining as there are other CSPGs in PNNs for WFA to bind to. 
WFA allows for visualization of PNNs as it binds to the N-acetylgalactosamines beta 1 
(GalNAc beta 1-3 Gal) residues on CSPGs (Hilbig et al., 2001). Aggrecan is known to 
contain around 100 GAG chains, while other CSPGs including neurocan and brevican 
contain as little as 0-5 (Siebert et al., 2014). Due to the relative amount of GAG 
sidechains on CSPGs, it is likely that WFA binding is more indicative of aggrecan, 
containing a high number of GAG sidechains, than other CSPGs. Thus, I may not have 
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found differences in WFA staining because aggrecan expression levels were not reduced 
in Sox9 KOs. 
In a previous study, we ablated Sox9 just prior to SCI and found decreases in PNN 
levels, increased reactive sprouting and improved locomotor recovery at 14 weeks post-
SCI. Why does ablating Sox9 at a more chronic time-point, 30 days post-injury, not have 
the same effect? The most likely explanation is that decreases in CSPG mRNA levels 
achieved by Sox9 KO, did not translate into decreased CSPG protein content within the 
PNN structure. It has been shown that CSPGs in PNNs have a very slow turnover rate 
(Tsien, 2013; Zimmermann and Dours-Zimmermann, 2008). Margolis et al. (1975) used 
labeled threonine to calculate the half-life of glycoproteins in the brain and threonine 
radioactivity showed a biphasic decay in glycoproteins with half-lives of 13 and 38 days. 
However, they did not observe any incorporation of threonine into glycosaminoglycans 
and could not measure the half-life of protein in chondroitin sulfate (Margolis et al., 
1975). This suggests that the turnover of CSPGs in PNNs is very slow (Tsien, 2013). 
Matrix metalloproteinases (MMPs) are endogenous endopeptidases that digest PNNs 
(Tsien, 2013). After spinal cord injury in mice, MMP-9 activity peaks at 24 hours, is 
greatly reduced at 48 hours, and is all but absent by 7 days post-SCI (Noble et al., 2002). 
This means that CSPGs are being degraded by MMPs shortly after injury. We have 
shown that SOX9 levels increase 12-fold at 12 hours post-SCI (Gris et al., 2007). This 
increased SOX9 expression leads to increases in C4ST, XT-1 and CSPG core proteins 
neurocan, brevican and aggrecan 1 week after injury. Thus, the breakdown of CSPGs by 
MMP activity is compensated for by higher levels of SOX9 activity and increased 
synthesis of CSPGs. SOX9 ablation just prior to SCI prevents the expression of genes 
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involved in CSPG production (core proteins and biosynthetic enzymes) and the 
consequent lack of CSPG synthesis combined with increased degradation by MMPs leads 
to decreased CSPG levels at the lesion (glial scar) and caudal to the lesion (within PNNs) 
in Sox9 KO mice. This decrease makes the molecular environment of the spinal cord 
more permissive to plasticity, and is why we found increased reactive sprouting and 
locomotor recovery when we ablated Sox9 prior to injury. I suggest that in the present 
study in which Sox9 is ablated well after MMP activity has ceased to be detectable (after 
1 week post-injury), CSPG levels remain unchanged from baseline levels because in the 
absence of MMP activity CSPG turnover is extremely low. This explanation is in keeping 
with our prior demonstration that if MMP activity is inhibited concurrently with 
conditional Sox9 ablation at the time of SCI, CSPG levels do not decrease nor is there any 
improvement in locomotor recovery (McKillop et al., 2016). Thus, both the presence of 
MMPs and Sox9 ablation is needed to effectively decrease CSPG rich PNNs (Figure 9).  
My next question was whether ablating Sox9 weeks after injury would allow for 
axonal sprouting to occur. Quantification of BDA puncta in the ventral horns below the 
level of the lesion demonstrated no differences in labeled corticospinal tract neurons in 
Sox9 KO mice versus controls. After discovering that Sox9 ablation 30 days after SCI 
does not decrease the amount of PNNs at or below the lesion, it was expected that no 
neuroplasticity would occur. Without decreased PNNs, the molecular environment of the 
spinal cord remains inhibitory to axonal sprouting. If PNNs were decreased in Sox9 KO 
mice, I would have expected these mice to have increased BDA labeling signifying 
increased neuroplasticity.  
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MMP 
Figure 9. Diagram describing how Sox9 ablation leads to increased 
neuroplasticity. Prior to SCI, the neuron illustrated on the left receives many 
inputs. After SCI, there is a loss of inputs synapsing on the neuron and only inputs 
from spared axons remain. SOX9 activity increases synthesis of CSPGs which 
limit neuroplasticity. When no SOX9 is present, there are decreased levels of 
CSPGs in PNNs, which allows axonal branching to occur from spared fibres to 
compensate for the loss of synaptic input on neurons.  However, this response only 
occurs in acute stages of SCI because turnover of CSPGs is high due to the 
increased presence of MMPs. In chronic stages of SCI, MMP levels are not high, 
turnover of CSPGs is low, and ablation of Sox9 does not lead to decreases in 
CSPGs. Therefore, both Sox9 ablation and the presence of MMPs is needed to 
decrease PNN CSPGs.  
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An alternate explanation for why axonal sprouting did not take place could be that 
neurons did not possess an intrinsic ability for sprouting in chronic stages of SCI. 
Intrinsic factors would include proteins expressed within neurons that promote axonal 
growth and sprouting. For example, ß-actin and GAP-43 are two proteins that support 
axon branching and elongation, respectively (Donnelly et al., 2013). Expression of some 
of these proteins may be increased shortly after SCI, thus promoting axon sprouting in the 
acute phases of SCI. It has been found that 1-4 days after injury growth associated protein 
(GAP) 43 immunoreactivity is increased in axons after mild and moderate compression 
SCI in rats, but begins to decrease 9 days post-injury (Li et al., 1996). This means that in 
the first few days after SCI, axon elongation may be supported due to the presence of 
GAP-43. 
Extrinsic factors in the injured spinal cord microenvironment such as those in 
myelin, could also explain why neuroplasticity did not occur. There are molecules present 
in myelin that limit neuroplasticity including Nogo, myelin-associated glycoprotein, 
oligodendrocyte myelin glycoprotein, netrin, and ephrin (Vourc'h and Andres, 2004; 
Kempf and Schwab, 2013; Blesch and Tuszynski, 2009). It is possible that in the acute 
phases of SCI these molecules decrease in expression allowing for sprouting to occur, and 
return to baseline levels at later time-points. For example, Nogo-A protein and mRNA 
expression are low 24 hours after SCI in rats, and at their lowest 3 days post-injury 
(Wang et al., 2015). They then peak at 7 days and drop only slightly 14 days following 
SCI (Wang et al., 2015). This means that in the acute phases of SCI, inhibition on axon 
outgrowth by this myelin-associated molecule is low, but increases at later time points 
making it a greater challenge to induce plasticity later than a week after SCI.  
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Since neuroplasticity did not increase in Sox9 KO mice as assessed with BDA, 
improvements in recovery were not expected to occur. Locomotor recovery was recorded 
for 14 weeks using the BMS to assess hindlimb function. Both Sox9 KO mice and 
controls improved significantly with respect to time. This was expected as spontaneous 
natural recovery does occur following SCI. However, Sox9 KO mice did not show greater 
hindlimb recovery compared to controls.  
When the location of the lesion was landmarked, I discovered that the injury was 
centered at the L1 level whereas I planned for the injury to be located at T9. A contusion 
injury directly on the lumbar enlargement would physically damage the alpha motor 
neurons that innervate hindlimb muscles. Thus, any sprouting that occurs onto these 
motor neurons may not improve hindlimb movement. It is formally possible that I did not 
find differences in the BMS score, which reflects hindlimb movement, between Sox9 KO 
and control mice because of my lesion location. Therefore, I generated another group of 
spinal cord injured animals possessing a lesion at T9 to re-assess locomotor recovery. It 
was found that Sox9 KO mice with a T9 lesion also did not show improved hindlimb 
recovery compared to controls. Therefore, I can affirm that the lack of improved recovery 
is due to the absence of sprouting as opposed to neuronal destruction at the lumbar 
enlargement.   
As our laboratory has a research program dedicated to identifying and preclinical 
testing of SOX9 inhibitors it is interesting to consider what this study says about the 
likely therapeutic usefulness of SOX9 inhibition after SCI. My findings suggest that if a 
SOX9 inhibitor is to be administered on its own then it will need to be delivered in the 
acute period of SCI when MMP activity (and hence CSPG turnover) is high. In the mouse 
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model of SCI, this period is defined by a period of days (Hansen et al., 2013). However, 
there are differences in the start and duration of inflammation between rodents and 
humans, which suggest that a window for the administration of a SOX9 inhibitor may be 
weeks or months in the human (Hansen et al., 2013). Immunohistochemical analyses of 
post mortem human spinal cords from controls and patients who sustained a SCI reveal 
that expression of MMP-9 rises progressively from 5 to 24 days post-injury, while MMP-
12 experiences an isolated peak of expression at 24 days post-injury (Buss et al., 2007). 
Based on these results, a SOX9 inhibitor may prove effective in humans when 
administered up to 24 days following spinal cord injury.   
For the treatment for chronic SCI, my results suggest that a method to increase the 
turnover of CSPGs should be applied before or at the same time as the SOX9 inhibitor. 
This process may be possible by inducing an acute inflammatory response in the cord, as 
inflammation has been known to induce MMP production by glial cells, endothelial cells, 
and leukocytes (Hansen et al., 2013; Buss et al., 2007). Lipopolysacharide (LPS) can be 
injected to induce an inflammatory response (Rosenberg, 2002). It has been shown that 
LPS induces the expression of MMP in human monocytes and macrophages, and murine 
macrophages and astrocytes (Ho et al., 2008; Woo et al., 2004; Lee et al., 2003). With 
these treatment combinations, CSPGs will be effectively degraded and the body not 
capable of replenishing their levels due to Sox9 ablation.  
Perhaps the best therapeutic approach to SCI will be strategies that in addition to 
removing impediments to sprouting also promote growth of axons. Expression of a 
variety of growth associated proteins and signals are required within the neuron and axon 
to be able to sense extracellular matrix cues and trophic factors that guide sprouting 
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(Blesch and Tuszynski, 2009). Thus, an effective treatment for chronic SCI will likely 
consist of a combinatorial treatment targeting both the axon’s ability to grow, and the 
inhibitory molecular environment of the injured spinal cord. One method that primes 
axons for sprouting is to increase their activity, which can be accomplished through 
electrical stimulation or rehabilitation (Onifer et al., 2011). Rehabilitation for spinal cord 
injured patients is currently the most effective treatment for improving locomotor and 
sensory recovery (Onifer et al., 2011). It is believed that rehabilitation, as well as 
electrical stimulation, increase levels of 3'-5'-cyclic adenosine monophosphate (cAMP) 
and brain-derived neurotrophic factor (BDNF), molecules known to increase 
neuroplasticity (Onifer et al., 2011). Increased cAMP levels cause upregulation of 
growth-associated genes in the neuron, while BDNF is a trophic factor that affects 
synaptic plasticity (Qiu et al., 2002; Ying et al., 2008). Wang et al. (2011) demonstrated 
the effects of a combination treatment consisting of chondroitinase administration and 
rehabilitation in rats after a C4 SCI. Rats given the combination treatment performed 
better at skilled paw reaching than rats given chondroitinase or rehabilitation alone (Wang 
et al., 2011). Furthermore, the administration of this combination treatment was 
performed 1 month after SCI, thus showing efficacy in a chronic model of injury. Trophic 
factors also seem likely as candidates for inclusion in a combination treatment in order to 
provide a cue for axon outgrowth. Neurotrophin-3 has been shown to increase sprouting 
of the CST in rats after SCI and is one of a few possible neurotrophins that could be 
utilized (Schnell et al., 1994). Combinatorial treatments, including those utilizing 
neurotrophins and cAMP, are actively being researched and have shown success in 
promoting axonal regeneration (Lu et al., 2004; Pearse et al., 2004; Schnell et al., 1994).   
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In my study, I set out to find whether ablation of the SOX9 transcription factor in chronic 
SCI shows the same benefits as in acute ablation. I found that this was not the case. 
Ablation of Sox9 30 days after SCI did not lead to decreased levels of PNNs, increased 
reparative sprouting, or improved locomotor recovery. I have argued that this lack of 
effect is due to the slow turnover of CSPGs in the spinal cord and that a future SOX9 
inhibitor should be applied with treatments targeting CSPG degradation. It is important to 
define a therapeutic time window when investigating specific treatments for SCI, as early 
intervention may not be possible. Physicians must often wait until a patient is stable after 
experiencing trauma to the cord before a therapy can be administered. Thus, treatments 
for SCI may have to be applied days after an injury has been sustained. Furthermore, 
there are many individuals with longstanding SCI who would benefit from treatment 
applied during chronic phases of injury. Although there are no current treatments for SCI, 
investigations focused on increasing reparative sprouting may yield promising results. 
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